BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 11109977)

  • 21. Effect of the menopause and hormone replacement therapy on the carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen.
    Hassager C; Risteli J; Risteli L; Christiansen C
    Osteoporos Int; 1994 Nov; 4(6):349-52. PubMed ID: 7696831
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women.
    Garnero P; Tsouderos Y; Marton I; Pelissier C; Varin C; Delmas PD
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2390-7. PubMed ID: 10404809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Markers of bone turnover in postmenopausal women receiving hormone replacement therapy.
    Hamwi A; Ganem AH; Grebe C; Kerschan-Schindl K; Preisinger E; Boschitsch E; Bieglmayer C
    Clin Chem Lab Med; 2001 May; 39(5):414-7. PubMed ID: 11434391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.
    Marcus R; Holloway L; Wells B; Greendale G; James MK; Wasilauskas C; Kelaghan J
    J Bone Miner Res; 1999 Sep; 14(9):1583-95. PubMed ID: 10469288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.
    Garnero P; Sornay-Rendu E; Chapuy MC; Delmas PD
    J Bone Miner Res; 1996 Mar; 11(3):337-49. PubMed ID: 8852944
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Levonorgestrel and 17beta-estradiol given transdermally for the prevention of postmenopausal osteoporosis.
    Warming L; Ravn P; Christiansen C
    Maturitas; 2005 Feb; 50(2):78-85. PubMed ID: 15653003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
    Dane C; Dane B; Cetin A; Erginbas M
    Gynecol Endocrinol; 2007 Jul; 23(7):398-403. PubMed ID: 17701771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline.
    Okabe R; Inaba M; Nakatsuka K; Miki T; Naka H; Moriguchi A; Nishizawa Y
    J Bone Miner Metab; 2004; 22(2):127-31. PubMed ID: 14999523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides.
    Christgau S; Rosenquist C; Alexandersen P; Bjarnason NH; Ravn P; Fledelius C; Herling C; Qvist P; Christiansen C
    Clin Chem; 1998 Nov; 44(11):2290-300. PubMed ID: 9799756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of short-term treatment with micronized estradiol on bone turnover and gonadotrophins in older men.
    Taxel P; Kennedy D; Fall P; Willard A; Shoukri K; Clive J; Raisz LG
    Endocr Res; 2000 Aug; 26(3):381-98. PubMed ID: 11019903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease.
    Garnero P; Gineyts E; Riou JP; Delmas PD
    J Clin Endocrinol Metab; 1994 Sep; 79(3):780-5. PubMed ID: 8077361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability.
    Hannon R; Blumsohn A; Naylor K; Eastell R
    J Bone Miner Res; 1998 Jul; 13(7):1124-33. PubMed ID: 9661076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in bone turnover following gonadotropin-releasing hormone (GnRH) agonist administration and estrogen treatment in cynomolgus monkeys: a short-term model for evaluation of antiresorptive therapy.
    Stroup GB; Hoffman SJ; Vasko-Moser JA; Lechowska BA; Jenkins EL; Dare LC; Gowen M
    Bone; 2001 May; 28(5):532-7. PubMed ID: 11344053
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma.
    Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Biondi B; Iorio S; Giustina A; Amato G; Carella C
    J Bone Miner Res; 2005 Mar; 20(3):480-6. PubMed ID: 15746993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vitamin D receptor and estrogen receptor gene polymorphisms in postmenopausal Danish women: no relation to bone markers or serum lipoproteins.
    Bagger YZ; Hassager C; Heegaard AM; Christiansen C
    Climacteric; 2000 Jun; 3(2):84-91. PubMed ID: 11910656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of serum FSH measurement on bone resorption in postmenopausal women.
    García-Martín A; Reyes-García R; García-Castro JM; Rozas-Moreno P; Escobar-Jiménez F; Muñoz-Torres M
    Endocrine; 2012 Apr; 41(2):302-8. PubMed ID: 21964645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in bone turnover during the menstrual cycle in cynomolgus monkeys.
    Hotchkiss CE; Brommage R
    Calcif Tissue Int; 2000 Mar; 66(3):224-8. PubMed ID: 10666499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation.
    Rosen CJ; Chesnut CH; Mallinak NJ
    J Clin Endocrinol Metab; 1997 Jun; 82(6):1904-10. PubMed ID: 9177404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Comparison of changes in biochemical markers of bone turnover after 6 months of hormone replacement therapy with either transdermal 17 beta-estradiol or equine conjugated estrogen plus nomegestrol acetate].
    Collette J; Viethel P; Dethor M; Chevallier T; Micheletti MC; Foidart JM; Reginster JY
    Gynecol Obstet Fertil; 2003 May; 31(5):434-41. PubMed ID: 14567121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women.
    Papakitsou EF; Margioris AN; Dretakis KE; Trovas G; Zoras U; Lyritis G; Dretakis EK; Stergiopoulos K
    Maturitas; 2004 Mar; 47(3):185-93. PubMed ID: 15036488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.